Excelsior Medical Co., Ltd. (4104.TW)
TWD 86.1
(-0.35%)
TWD 86.1
(-0.35%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.62 Billion TWD | 7.14% |
| 2022 | 1.51 Billion TWD | 10.19% |
| 2021 | 1.37 Billion TWD | 5.16% |
| 2020 | 1.3 Billion TWD | 5.51% |
| 2019 | 1.23 Billion TWD | 3.28% |
| 2018 | 1.19 Billion TWD | -0.65% |
| 2017 | 1.2 Billion TWD | 0.77% |
| 2016 | 1.19 Billion TWD | -2.71% |
| 2015 | 1.23 Billion TWD | 4.24% |
| 2014 | 1.18 Billion TWD | 2.27% |
| 2013 | 1.15 Billion TWD | -15.02% |
| 2012 | 1.35 Billion TWD | -4.61% |
| 2011 | 1.42 Billion TWD | -6.72% |
| 2010 | 1.52 Billion TWD | 20.34% |
| 2009 | 1.26 Billion TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 411.23 Million TWD | 3.12% |
| 2024 Q1 | 398.78 Million TWD | -8.33% |
| 2023 Q4 | 435 Million TWD | 8.11% |
| 2023 Q2 | 416.05 Million TWD | 2.78% |
| 2023 Q3 | 402.35 Million TWD | -3.29% |
| 2023 FY | 1.62 Billion TWD | 7.14% |
| 2023 Q1 | 404.79 Million TWD | -0.85% |
| 2022 Q2 | 358.28 Million TWD | -6.29% |
| 2022 Q3 | 365.18 Million TWD | 1.93% |
| 2022 Q4 | 408.24 Million TWD | 11.79% |
| 2022 FY | 1.51 Billion TWD | 10.19% |
| 2022 Q1 | 382.32 Million TWD | 3.57% |
| 2021 FY | 1.37 Billion TWD | 5.16% |
| 2021 Q3 | 325.43 Million TWD | -2.73% |
| 2021 Q4 | 369.13 Million TWD | 13.43% |
| 2021 Q1 | 344.9 Million TWD | 1.86% |
| 2021 Q2 | 334.55 Million TWD | -3.0% |
| 2020 Q2 | 308.68 Million TWD | -12.45% |
| 2020 Q1 | 352.58 Million TWD | 13.49% |
| 2020 Q3 | 306.7 Million TWD | -0.64% |
| 2020 Q4 | 338.59 Million TWD | 10.4% |
| 2020 FY | 1.3 Billion TWD | 5.51% |
| 2019 Q2 | 319.84 Million TWD | 0.5% |
| 2019 Q4 | 310.66 Million TWD | 7.26% |
| 2019 FY | 1.23 Billion TWD | 3.28% |
| 2019 Q1 | 318.26 Million TWD | 8.35% |
| 2019 Q3 | 289.62 Million TWD | -9.45% |
| 2018 Q4 | 293.73 Million TWD | 1.24% |
| 2018 FY | 1.19 Billion TWD | -0.65% |
| 2018 Q3 | 290.13 Million TWD | -6.21% |
| 2018 Q2 | 309.33 Million TWD | 1.12% |
| 2018 Q1 | 305.9 Million TWD | 3.76% |
| 2017 Q3 | 308.24 Million TWD | 6.39% |
| 2017 Q1 | 314.08 Million TWD | 4.67% |
| 2017 Q2 | 289.74 Million TWD | -7.75% |
| 2017 FY | 1.2 Billion TWD | 0.77% |
| 2017 Q4 | 294.81 Million TWD | -4.36% |
| 2016 Q1 | 286.77 Million TWD | -10.65% |
| 2016 Q2 | 314.17 Million TWD | 9.55% |
| 2016 Q3 | 296.69 Million TWD | -5.57% |
| 2016 Q4 | 300.07 Million TWD | 1.14% |
| 2016 FY | 1.19 Billion TWD | -2.71% |
| 2015 Q2 | 326.76 Million TWD | 16.59% |
| 2015 Q1 | 280.26 Million TWD | -9.26% |
| 2015 FY | 1.23 Billion TWD | 4.24% |
| 2015 Q3 | 303.03 Million TWD | -7.26% |
| 2015 Q4 | 320.95 Million TWD | 5.91% |
| 2014 Q4 | 308.84 Million TWD | 6.8% |
| 2014 Q3 | 289.18 Million TWD | -8.01% |
| 2014 Q1 | 268.55 Million TWD | -10.76% |
| 2014 FY | 1.18 Billion TWD | 2.27% |
| 2014 Q2 | 314.35 Million TWD | 17.05% |
| 2013 Q3 | 280.71 Million TWD | -0.7% |
| 2013 Q1 | 290.42 Million TWD | -6.73% |
| 2013 FY | 1.15 Billion TWD | -15.02% |
| 2013 Q4 | 300.94 Million TWD | 7.21% |
| 2013 Q2 | 282.68 Million TWD | -2.66% |
| 2012 Q4 | 311.37 Million TWD | -1.9% |
| 2012 Q3 | 317.39 Million TWD | -13.74% |
| 2012 Q2 | 367.94 Million TWD | 1.34% |
| 2012 FY | 1.35 Billion TWD | -4.61% |
| 2012 Q1 | 363.08 Million TWD | 56.56% |
| 2011 Q2 | 390.3 Million TWD | -3.01% |
| 2011 Q1 | 402.41 Million TWD | -4.17% |
| 2011 FY | 1.42 Billion TWD | -6.72% |
| 2011 Q4 | 231.91 Million TWD | -42.01% |
| 2011 Q3 | 399.94 Million TWD | 2.47% |
| 2010 Q3 | 379.63 Million TWD | -2.03% |
| 2010 FY | 1.52 Billion TWD | 20.34% |
| 2010 Q4 | 419.9 Million TWD | 10.61% |
| 2010 Q1 | 340.17 Million TWD | 0.0% |
| 2010 Q2 | 387.48 Million TWD | 13.91% |
| 2009 FY | 1.26 Billion TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Apex Medical Corp. | 1.13 Billion TWD | -42.499% |
| OK Biotech Co., Ltd. | 196.88 Million TWD | -723.882% |
| Applied BioCode Corporation | 268.73 Million TWD | -503.593% |